Replies to post #1381 on Vascular Biogenics Ltd (VBLT)

[staccani]

Yes, another way to put it, just to refine the analysis a bit... we know ca half of the patients were enrolled between September 2016 and November 2016 (mid point October 2016), but the remaining half was enrolled between Aug 2015 and Aug 2016 (of which ca 50 between Aug 2015 and May 2016 and ca 78 between June 2016 and Aug 2016).
So half of the patients has ca 12 months avg treatment and the other half ca 17.3 months as of October 2017.
Considering that the Avastin half should have ca 25% survival at 12 months, then VBL111 should have 25% survival at 17.3 months if the 189th is reached in October, otherwise 18.3 mnths in November, 19.3 mnths in December and so on so forth.
In any case, if Avastin arm behaves as historical and since 189th event not reached yet, VBL111 should already show a significant survival improvement of most likely 50%+ vs Avastin